OTCMKTS:ENZN - Enzon Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.23 0.00 (0.00 %) (As of 04/25/2019 04:00 PM ET)Previous Close$0.23Today's Range$0.23 - $0.2452-Week Range$0.1901 - $0.2910Volume52,200 shsAverage Volume42,755 shsMarket Capitalization$10.17 millionP/E RatioN/ADividend YieldN/ABeta0.23 ProfileDiscussionChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron for use in the treatment of chronic hepatitis C; and Sylatron for use in the treatment of melanoma disease. The company was founded in 1981 and is headquartered in Cranford, New Jersey. Receive ENZN News and Ratings via Email Sign-up to receive the latest news and ratings for ENZN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolOTCMKTS:ENZN Previous SymbolNASDAQ:ENZN CUSIP29390410 CIK727510 Webwww.enzon.com Phone732-980-4500Debt Debt-to-Equity RatioN/A Current Ratio28.12 Quick Ratio28.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.92 million Price / Sales1.47 Cash Flow$0.1307 per share Price / Cash Flow1.76 Book Value$0.34 per share Price / Book0.68Profitability EPS (Most Recent Fiscal Year)N/A Net Income$5.85 million Net MarginsN/A Return on Equity57.60% Return on Assets54.91%Miscellaneous EmployeesN/A Outstanding Shares44,215,000Market Cap$10.17 million Next Earnings Date5/9/2019 (Estimated) OptionableNot Optionable Enzon Pharmaceuticals (OTCMKTS:ENZN) Frequently Asked Questions What is Enzon Pharmaceuticals' stock symbol? Enzon Pharmaceuticals trades on the OTCMKTS under the ticker symbol "ENZN." How were Enzon Pharmaceuticals' earnings last quarter? Enzon Pharmaceuticals Inc (OTCMKTS:ENZN) announced its earnings results on Wednesday, August, 10th. The biotechnology company reported $0.02 earnings per share for the quarter. The biotechnology company had revenue of $2.27 million for the quarter. View Enzon Pharmaceuticals' Earnings History. When is Enzon Pharmaceuticals' next earnings date? Enzon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Enzon Pharmaceuticals. Has Enzon Pharmaceuticals been receiving favorable news coverage? News headlines about ENZN stock have trended somewhat positive this week, InfoTrie reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Enzon Pharmaceuticals earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. Who are some of Enzon Pharmaceuticals' key competitors? Some companies that are related to Enzon Pharmaceuticals include Microbot Medical (MBOT), Vical (VICL), Titan Pharmaceuticals (TTNP), aTyr Pharma (LIFE), TRACON Pharmaceuticals (TCON), Outlook Therapeutics (OTLK), CytRx (CYTR), TrovaGene (TROV), Windtree Therapeutics (WINT), Aevi Genomic Medicine (GNMX), Genetic Technologies (GENE), Neuralstem (CUR), Proteon Therapeutics (PRTO), Mymetics (MYMX) and Vaxart (VXRT). What other stocks do shareholders of Enzon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enzon Pharmaceuticals investors own include Biocept (BIOC), Energy Transfer LP Unit (ET), Nymox Pharmaceutical (NYMX), Cornerstone Total Return Fund (CRF), Marathon Patent Group (MARA), Novavax (NVAX), CBL & Associates Properties (CBL), SandRidge Permian Trust (PER), Cornerstone Strategic Value Fund (CLM) and AEterna Zentaris (AEZS). Who are Enzon Pharmaceuticals' key executives? Enzon Pharmaceuticals' management team includes the folowing people: Mr. Andrew Rackear, CEO & Sec. (Age 65)Mr. Richard L. Feinstein, VP of Fin. & CFO (Age 76) How do I buy shares of Enzon Pharmaceuticals? Shares of ENZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Enzon Pharmaceuticals' stock price today? One share of ENZN stock can currently be purchased for approximately $0.23. How big of a company is Enzon Pharmaceuticals? Enzon Pharmaceuticals has a market capitalization of $10.17 million and generates $6.92 million in revenue each year. What is Enzon Pharmaceuticals' official website? The official website for Enzon Pharmaceuticals is http://www.enzon.com. How can I contact Enzon Pharmaceuticals? Enzon Pharmaceuticals' mailing address is 20 Commerce Drive Suite 135, Cranford NJ, 07016. The biotechnology company can be reached via phone at 732-980-4500 or via email at [email protected] MarketBeat Community Rating for Enzon Pharmaceuticals (OTCMKTS ENZN)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 81 (Vote Outperform)Underperform Votes: 57 (Vote Underperform)Total Votes: 138MarketBeat's community ratings are surveys of what our community members think about Enzon Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENZN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/25/2019 by MarketBeat.com StaffFeatured Article: What is the S&P 500 Index?